mRNA Vaccine for Melanoma Shows Significant Efficacy in Preventing Recurrence
A recent study has shown that a personalized mRNA vaccine, developed by Moderna in collaboration with Merck, is highly effective in preventing the recurrence of melanoma when used alongside the immunotherapy drug Keytruda. The trial, which included 157 patients from the U.S. and Australia, demonstrated that the combination therapy reduced the risk of cancer recurrence by 49% over five years. The vaccine is tailored to each patient's tumor, using mRNA technology to train the immune system to recognize and attack specific neoantigens associated with the cancer. This approach has shown promising results, with 68.8% of patients remaining cancer-free after five years, compared to 49.1% who received only Keytruda. 
